Table 2.
CLINICAL BURDEN OF HCV SHOWING THE EHM RISK IN THE MATCHED HCV VERSUS NO‐HCV COHORTS
| Frequency of Specific EHMs n (%) | Odds Ratio HCV Versus No‐HCV Cohorts (95% CI) | |||
|---|---|---|---|---|
| No‐HCV Cohort | HCV Cohort | Before Adjustment | After Adjustment | |
| Specific EHMs | n = 85,270 | n = 17,054 | for Comorbidities | for Comorbidities |
| Cardiovascular disease | 12,020 (14.1%) | 3,853 (22.6%) | 1.83 (1.76, 1.91)a | 1.64 (1.57, 1.71)a |
| Metabolic conditionsb | 13,844 (16.2%) | 3,495 (20.5%) | 1.35 (1.29, 1.41)a | 1.26 (1.20, 1.31)a |
| Type 2 diabetes mellitus | 13,271 (15.6%) | 3,415 (20.0%) | 1.38 (1.32, 1.44)a | 1.28 (1.23, 1.34)a |
| Insulin resistance | 896 (1.1%) | 146 (0.9%) | 0.81 (0.68, 0.97)a | 0.80 (0.67, 0.96)a |
| Kidney diseaseb | 2,960 (3.5%) | 1,608 (9.4%) | 2.98 (2.79, 3.18)a | 2.58 (2.40, 2.77)a |
| Nephritis/Nephrotic syndrome /Nephrosis | 1,493 (1.8%) | 1,062 (6.2%) | 3.79 (3.49, 4.11)a | 3.22 (2.94, 3.54)a |
| Chronic kidney disease | 2,303 (2.7%) | 1,200 (7.0%) | 2.80 (2.60, 3.01)a | 2.39 (2.20, 2.59)a |
| Auto‐immune conditionsb | 2,218 (2.6%) | 758 (4.4%) | 1.75 (1.60, 1.90)a | 1.70 (1.56, 1.86)a |
| Celiac disease | 133 (0.2%) | 66 (0.4%) | 2.49 (1.85, 3.34)a | 2.39 (1.75, 3.25)a |
| Inflammatory bowel disease | 766 (0.9%) | 296 (1.7%) | 1.95 (1.70, 2.23)a | 1.81 (1.57, 2.08)a |
| Psoriasis | 1,344 (1.6%) | 408 (2.4%) | 1.53 (1.37, 1.71)a | 1.56 (1.39, 1.75)a |
| Malignancyb | 2,152 (2.5%) | 533 (3.1%) | 1.25 (1.14, 1.38)a | 1.21 (1.10, 1.34)a |
| Non‐Hodgkin's lymphoma | 424 (0.5%) | 196 (1.1%) | 2.33 (1.97, 2.77)a | 2.23 (1.87, 2.66)a |
| Prostate cancer | 1,234 (1.4%) | 199 (1.2%) | 0.80 (0.69, 0.93)a | 0.79 (0.67, 0.92)a |
| Head and neck cancers | 236 (0.3%) | 95 (0.6%) | 2.02 (1.59, 2.56)a | 2.09 (1.62, 2.69)a |
| Thyroid cancer | 278 (0.3%) | 36 (0.2%) | 0.65 (0.46, 0.92)a | 0.65 (0.46, 0.93)a |
| Esophageal cancer | 35 (0.0%) | 27 (0.2%) | 3.86 (2.33, 6.37)a | 4.48 (2.58, 7.75)a |
| Neuromuscular manifestationsb | 19,020 (22.3%) | 5,659 (33.2%) | 1.76 (1.70, 1.83)a | 1.68 (1.62, 1.74)a |
| Chronic fatigue syndrome/Fatigue | 15,708 (18.4%) | 4,842 (28.4%) | 1.79 (1.72, 1.86)a | 1.70 (1.63, 1.77)a |
| Fibromyalgia | 4,935 (5.8%) | 1,440 (8.4%) | 1.51 (1.42, 1.61)a | 1.47 (1.38, 1.56)a |
| Parkinson's disease | 166 (0.2%) | 43 (0.3%) | 1.30 (0.93, 1.82) | 1.19 (0.83, 1.70) |
| Otherb | 18,190 (21.3%) | 6,216 (36.4%) | 2.15 (2.08, 2.23)a | 2.03 (1.95, 2.10)a |
| Irritable bowel syndrome | 1,291 (1.5%) | 343 (2.0%) | 1.34 (1.19, 1.51)a | 1.31 (1.16, 1.48)a |
| Cognitive impairment | 387 (0.5%) | 161 (0.9%) | 2.11 (1.75, 2.54)a | 1.91 (1.55, 2.37)a |
| Depression | 6,773 (7.9%) | 2,885 (16.9%) | 2.40 (2.29, 2.52)a | 2.26 (2.15, 2.38)a |
| Gastroesophageal reflux disease | 12,284 (14.4%) | 4,034 (23.7%) | 1.86 (1.79, 1.94)a | 1.75 (1.68, 1.83)a |
| Any of the above listed EHMs, n (%) | 44,510 (52.2%) | 11,971 (70.2%) | 2.29 (2.21, 2.38)a | 2.23 (2.15, 2.31)a |
a
P < 0.05.
b
Any of the specific EHMs listed in the category.